| Epidemiology and Risk Factors in Diabetic Retinopathy and Diabetic Macular Edema | Nurullah KOÇAK | 89–93 |
| Pathogenesis of Diabetic Retinopathy and Diabetic Macular Edema | HÜRKAN KERİMOĞLU,Hüseyin Buğra TÜRK | 94–101 |
| Systemic and Genetic Risk Factors in Diabetic Retinopathy and Diabetic Macular Edema | Süleyman DEMİRCAN,Emine PANGAL | 102–107 |
| Screening, Follow-up and Treatment Algorithm in Diabetic Retinopathy and Maculopathy | HALİL ÖZGÜR ARTUNAY,Beril TÜLÜ,ELVAN ALPER ŞENGÜL,İrfan PERENTE | 108–118 |
| Clinical Diagnosis and New Classifications in Diabetic Retinopathy and Diabetic Macular Edema | Sema ARVAS,Aslıhan YILMAZ ÇEBİ | 119–123 |
| Differential Diagnoses in Diabetic Optic Neuropathies: Diabetic Papillopathy, Ischemic Optic Neuropathy and Optic Atrophy | Ertuğrul Tan YASSA,Berker BAKBAK | 124–129 |
| Fundus Fluorescein Angiography and Optical Coherence Tomography Angiography Findings in Diabetic Retinopathy and Diabetic Macular Edema | Yusuf Kemal DURLU,Işılay KAVADARLI | 130–137 |
| Optical Coherence Tomography Findings in Diabetic Retinopathy and Diabetic Macular Edema | HAKAN ÖZDEMİR,Cansu EKİNCİ | 138–142 |
| Ranibizumab Treatment and Protocols in Diabetic Retinopathy and Diabetic Macular Edema | Didar UÇAR,Samira HAGVERDİYEVA,Gülipek TİGREL | 143–146 |
| Aflibercept for the Treatment of Diabetic Retinopathy and Diabetic Macular Edema | Emine TEMEL,FİGEN ŞERMET | 147–154 |
| Bevacizumab and Treatment Regimes in Diabetic Retinopathy and Diabetic Macular Edema | Ökkeş BAZ,ABDULLAH ÖZKAYA | 155–159 |
| Steroid Therapy in Diabetic Retinopathy and Diabetic Macular Edema | Günhal ŞATIRTAV | 160–164 |
| Anti-VEGF Deficiency, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Diabetic Macular Edema | Sema ORUÇ DÜNDAR,HARUN ÇAKMAK | 165–169 |